α-Synuclein in Parkinson's Disease

被引:883
|
作者
Stefanis, Leonidas [1 ,2 ]
机构
[1] Acad Athens, Biomed Res Fdn, Lab Neurodegenerat Dis, Athens 11527, Greece
[2] Univ Athens, Sch Med, Dept Neurol 2, GR-11527 Athens, Greece
来源
关键词
CHAPERONE-MEDIATED AUTOPHAGY; DOPAMINERGIC NEURONAL LOSS; NIGRA PARS COMPACTA; BETA-SYNUCLEIN; WILD-TYPE; DROSOPHILA MODEL; LEWY BODIES; IN-VIVO; INCLUSION FORMATION; MOUSE MODEL;
D O I
10.1101/cshperspect.a009399
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
alpha-Synuclein is a presynaptic neuronal protein that is linked genetically and neuropathologically to Parkinson's disease (PD). alpha-Synuclein may contribute to PD pathogenesis in a number of ways, but it is generally thought that its aberrant soluble oligomeric conformations, termed protofibrils, are the toxic species that mediate disruption of cellular homeostasis and neuronal death, through effects on various intracellular targets, including synaptic function. Furthermore, secreted alpha-synuclein may exert deleterious effects on neighboring cells, including seeding of aggregation, thus possibly contributing to disease propagation. Although the extent to which alpha-synuclein is involved in all cases of PD is not clear, targeting the toxic functions conferred by this protein when it is dysregulated may lead to novel therapeutic strategies not only in PD, but also in other neurodegenerative conditions, termed synucleinopathies.
引用
收藏
页数:23
相关论文
共 50 条
  • [31] α-Synuclein in Parkinson’s disease: causal or bystander?
    Peter Riederer
    Daniela Berg
    Nicolas Casadei
    Fubo Cheng
    Joseph Classen
    Christian Dresel
    Wolfgang Jost
    Rejko Krüger
    Thomas Müller
    Heinz Reichmann
    Olaf Rieß
    Alexander Storch
    Sabrina Strobel
    Thilo van Eimeren
    Hans-Ullrich Völker
    Jürgen Winkler
    Konstanze F. Winklhofer
    Ullrich Wüllner
    Friederike Zunke
    Camelia-Maria Monoranu
    [J]. Journal of Neural Transmission, 2019, 126 : 815 - 840
  • [32] α-Synuclein in Parkinson's disease: causal or bystander?
    Riederer, Peter
    Berg, Daniela
    Casadei, Nicolas
    Cheng, Fubo
    Classen, Joseph
    Dresel, Christian
    Jost, Wolfgang
    Krueger, Rejko
    Mueller, Thomas
    Reichmann, Heinz
    Riess, Olaf
    Storch, Alexander
    Strobel, Sabrina
    van Eimeren, Thilo
    Voelker, Hans-Ullrich
    Winkler, Juergen
    Winklhofer, Konstanze F.
    Wuellner, Ullrich
    Zunke, Friederike
    Monoranu, Camelia-Maria
    [J]. JOURNAL OF NEURAL TRANSMISSION, 2019, 126 (07) : 815 - 840
  • [33] Familial Parkinson's disease α-synuclein and parkin
    Mizuno, Y
    Hattori, N
    Kitada, T
    Matsumine, H
    Mori, H
    Shimura, H
    Kubo, S
    Kobayashi, H
    Asakawa, S
    Minoshima, S
    Shimizu, N
    [J]. PARKINSON'S DISEASE, 2001, 86 : 13 - 21
  • [34] α-Synuclein in Parkinson's disease and advances in detection
    Chen, Rong
    Gu, Xuan
    Wang, Xiaoying
    [J]. CLINICA CHIMICA ACTA, 2022, 529 : 76 - 86
  • [35] Models of α-synuclein aggregation in Parkinson’s disease
    Rosa María Giráldez-Pérez
    Mónica Antolín-Vallespín
    María Dolores Muñoz
    Amelia Sánchez-Capelo
    [J]. Acta Neuropathologica Communications, 2
  • [36] α-Synuclein: A therapeutic target for Parkinson's disease?
    Maguire-Zeiss, Kathleen A.
    [J]. PHARMACOLOGICAL RESEARCH, 2008, 58 (5-6) : 271 - 280
  • [37] Environmental toxins and α-synuclein in Parkinson's disease
    Liu, YY
    Yang, H
    [J]. MOLECULAR NEUROBIOLOGY, 2005, 31 (1-3) : 273 - 282
  • [38] The Central Theme of Parkinson’s Disease: α-Synuclein
    Mehmet Ozansoy
    A. Nazli Başak
    [J]. Molecular Neurobiology, 2013, 47 : 460 - 465
  • [39] α-Synuclein and Lewy pathology in Parkinson's disease
    Kalia, Lorraine V.
    Kalia, Suneil K.
    [J]. CURRENT OPINION IN NEUROLOGY, 2015, 28 (04) : 375 - 381
  • [40] α-synuclein and Parkinson's disease:: the first roadblock
    Chua, Christelle En Lin
    Tang, Bor Luen
    [J]. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2006, 10 (04) : 837 - 846